Severity
Moderate
FDA Drug recall · Reported May 31, 2017
cGMP Deviations: lack of quality assurance at the API manufacturer.
Fagron, Inc recalled Estriol, For Prescription Compounding, packaged in a) 1 G bottle (NDC: 51552-1392-1), b) … - a moderate-severity action.
Estriol, For Prescription Compounding, packaged in a) 1 G bottle (NDC: 51552-1392-1), b) … was recalled by Fagron, Inc in May 31, 2017. Reason: cGMP Deviations: lack of quality assurance at the API manufacturer.. Check the official notice for the remedy. Verify recall #D-0791-2017 with the FDA Drug before acting.
The recall
Fagron, Inc issued this moderate-severity FDA Drug recall-cGMP Deviations: lack of quality assurance at the API manufacturer..
Sourced from official FDA Drug enforcement records. Verify recall #D-0791-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0791-2017) was formally reported on May 31, 2017, with the manufacturer initiating the action on April 6, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. Fagron, Inc is listed as the recalling firm, operating out of Saint Paul, MN. Federal records list the affected scope as 15283 grams.
The documented reason for this recall is: cGMP Deviations: lack of quality assurance at the API manufacturer. Distribution data in the federal record shows the product reached: Nationwide in US and PR and Australia. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
15283 grams
Related Recalls
6
5 from same agency
Estriol, For Prescription Compounding, packaged in a) 1 G bottle (NDC: 51552-1392-1), b) 5 G bottle (NDC: 51552-1392-2), c) 25 G bottle (NDC: 51552-1392-3), d) 100 G bottle (NDC: 51552-1392-5), RX only, Distributed by Fagron, Inc. 2400 Pilot Knob Rd, St. Paul, MN 55120 Tel. 1-(800) 423-6967 Also packaged as: Estriol USP Micronized, For prescription compounding, packaged in a 100 G bottle (NDC 52372-9292-01), Rx only, Distributed by FREEDOM, 801 W. New Orleans St. Broken Arrow, OK 74011
cGMP Deviations: lack of quality assurance at the API manufacturer.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0791-2017 |
| Date reported | May 31, 2017 |
| Date initiated | April 6, 2017 |
| Recalling firm | Fagron, Inc |
| Firm location | Saint Paul, MN |
| Affected scope | 15283 grams |
| Distribution | Nationwide in US and PR and Australia |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 31, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.